Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma

समान संसाधन

• Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma
  द्वारा: Owen, C., और अन्य
  प्रकाशित: (2019)
• Pleiotropic Action of Novel Bruton’s Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
  द्वारा: Li, Carrie J, और अन्य
  प्रकाशित: (2018)
• Proteasome inhibitors in mantle cell lymphoma
  द्वारा: Holkova, Beata, और अन्य
  प्रकाशित: (2012)
• Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
  द्वारा: Eyre, Toby A., और अन्य
  प्रकाशित: (2019)
• Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
  द्वारा: Chang, Betty Y., और अन्य
  प्रकाशित: (2013)